GLYCOMINDS DIAGNOSTICS (2014) LTD

Glycominds Diagnostics specializes in assay development analyte-specific reagent in vitro diagnostic (IVD) plates. These are designed for biochemical analysis, specifically to detect carbohydrate structures like saccharomyces, chitobioside, laminaribioside, and mannobioside in biological samples. The devices are tailored for research or diagnostic applications where precise detection of these analytes is required.

Glycominds Diagnostics is based in the United States, which means its devices must comply with FDA regulations. Since these products are classified as Class I medical devices, they undergo a lower level of regulatory scrutiny compared to higher-risk devices, but they still must meet FDA requirements for safety and performance. The company’s devices are listed in the FDA’s Unique Device Identifier (UDI) database, ensuring traceability and transparency in the regulatory system.

Glycominds Diagnostics’ devices are included in the FDA’s Unique Device Identifier (UDI) database. This registry ensures that each product has a standardized identifier for tracking, reporting, and compliance purposes. Listing in the UDI database is a requirement for Class I devices in the U.S., helping to maintain transparency and accountability in the medical device supply chain.

Glycominds Diagnostics’ assay development analyte-specific reagent IVD plates are classified as Class I medical devices under FDA regulations. This classification is based on their intended use—detecting specific carbohydrate structures in biological samples—and their relatively low risk profile. Class I devices typically pose minimal potential harm to users and require less stringent premarket review, though they still must comply with general controls and labeling requirements.